Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

192.45 -2.55 (-1.31%)
Official Closing Price Updated: 7:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection
FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data. 
Via Benzinga
Recent Filing Shows That Rep. Robert Bresnahan Bought Over $28K Worth of AbbVie Stock
Via Benzinga
1 S&P 500 Stock with Competitive Advantages and 2 to Steer Clear Of
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Economy Stocks
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Via The Motley Fool
Topics Intellectual Property
Billionaire Ken Griffin Just Bought More Shares of These Unstoppable Dividend Stocks
Via The Motley Fool
Topics Economy World Trade
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38. 
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Cheap Dividend Growth Stocks to Buy Right Now
Via The Motley Fool
Topics Economy
4 Forever Dividend Stocks to Buy
These companies provide growing cash flows. 
Via The Motley Fool
Meta, JPMorgan, Gap And A Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position? 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
AbbVie To Present Cancer Trial Data At Upcoming ASCO Event
AbbVie shares new data for Temab-A, ABBV-706, and PVEK across lung, colorectal, and blood cancers ahead of the ASCO oncology conference. 
Via Benzinga
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result
There's little doubt these pharmaceutical companies' costs will soon be rising at least a little. 
Via The Motley Fool
Topics Government Supply Chain World Trade
Elon Musk Commits to Tesla. Is That a Good Thing?
Via The Motley Fool
2 Incredible Dividend Growth Stocks to Buy Now
Via The Motley Fool
Topics Government Intellectual Property
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.
Here are three dividend-paying stocks that warrant closer examination. 
Via The Motley Fool
3 Magnificent Stocks That Are Passive Income Machines
Via The Motley Fool
3 Stocks That Will Profit From Trump's Drug Price Cut
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest. 
Via Benzinga
Topics Government
1 Healthcare Stock to Keep an Eye On and 2 to Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Economy Stocks
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity. 
Via Benzinga
Jim Cramer Says Even 'Safety' Stocks Look Risky, Warns Of 'Wild Card' In Washington And Rising Treasury Yields As Reasons To Stay Away From Sure Bets
Rising bond yields and uncertain politics make 'safety' stocks less appealing, says Jim Cramer. Even Procter & Gamble and Johnson & Johnson suddenly feel shaky to the market guru. 
Via Benzinga
Topics Bonds
Stay informed with the top movers within the S&P500 index on Wednesday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session. 
Via Chartmill
FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases
FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes $335 million upfront. 
Via Benzinga
AbbVie Gets FDA Nod For Drug To Treat Lung Cancer: Retail’s Yet To React
The company also announced a collaboration and license option agreement with ADARx Pharmaceuticals to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including... 
Via Stocktwits
What's going on in today's session: S&P500 movers
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Expert Outlook: AbbVie Through The Eyes Of 10 Analysts
Via Benzinga
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers. 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.